KLH-2109 for heavy menstrual bleeding from uterine fibroids

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a phase 3, multicenter, randomized, double-blind, active-controlled, parallel-group trial comparing KLH-2109 with a standard treatment in people with uterine fibroids and menorrhagia. Participants will take either KLH-2109 or the comparator pill (with matching placebos) and attend regular clinic visits for safety checks and monitoring. Participants will track their menstrual bleeding and symptoms during the treatment period to measure changes in blood loss and report any side effects. Key inclusion criteria are a diagnosis of uterine fibroids with heavy menstrual bleeding, and key exclusions include metrorrhagia, anovulatory bleeding, prior total hysterectomy, or bilateral oophorectomy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Individuals diagnosed with uterine fibroids

Exclusion Criteria:

* Metrorrhagia or anovulatory bleeding
* Patients with a history of total hysterectomy or bilateral oophorectomy

Where it's running

• Asan Medical Center
  Seoul, South Korea Recruiting

Study contacts

• Principal investigator: Jeong Yeol Park — Asan Medical Center
• Study coordinator: Deageun Song
• Email: daegeun.song@jwhealthcare.com
• Phone: 82-2-840-6792

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ablation system to treat abnormal uterine bleeding in women with prior cesarean delivery

  Aerospace-style? No—this trial tests a vapor ablation device to see if it safely reduces heavy or irregular bleeding in women with AUB who have had a cesarean delivery.

  Recruiting at 2 sites Aqua Therapeutics, Inc. · Feldkirch and 1 other locations · NCT07925008

• Predictors of Success and Failure of v-NOTES Hysterectomy for Large Uteri

  This study looks at which factors predict whether a v-NOTES hysterectomy for large uteri will be completed without needing to switch to another surgical approach.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07895953

• AquaTherapeutics Vapor Ablation for Abnormal Uterine Bleeding in Premenopausal Women

  This trial tests the Aqua Therapeutics Thermal Therapy Vapor Ablation System to treat abnormal uterine bleeding in premenopausal women who do not want to conceive.

  Recruiting at 3 sites Aqua Therapeutics, Inc. · Batumi and 2 other locations · NCT07877051

• Elix Cycle Balance and Elix Daily Harmony for fibroid-related symptoms

  This 24-week virtual study will test whether taking the herbal supplements Elix Cycle Balance and Elix Daily Harmony daily can reduce menstrual pain and other fibroid-related symptoms in women aged 20–45 with uterine fibroids.

  Recruiting Zenchi, Inc. · Las Vegas, Nevada · NCT07078682

• Relugolix treatment for heavy menstrual bleeding from uterine fibroids

  This trial will test whether taking relugolix 40 mg once daily can reduce heavy menstrual bleeding in premenopausal women with uterine fibroids compared with placebo.

  Recruiting Phase 3 Qilu Pharmaceutical Co., Ltd. · Beijing · NCT06671548

• Registry to collect real-world data on the Cerene Cryotherapy Device

  This study is collecting information from women who are using the Cerene Cryotherapy Device to treat heavy menstrual bleeding to see how well it works in real life compared to clinical studies.

  Recruiting Channel Medsystems · West Orange, New Jersey and 1 other locations · NCT05922657

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.